Sanofi | CIK:0001121404 | 3

  • Filed: 3/16/2018
  • Entity registrant name: Sanofi (CIK: 0001121404)
  • Generator: Donnelley Financial Solutions
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/0001193125-18-084834-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/sny-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001121404
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsExplanatory

    The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.

     

                 Method used to determine fair value
    Note    Type of financial instrument   Measurement
    principle    		   Valuation
    model    		   Market data
             Exchange rate   Interest rate
    D.7.    Available-for-sale financial assets (quoted equity securities)   Fair value   Quoted market price   N/A   N/A
    D.7.    Available-for-sale financial assets (quoted debt securities)   Fair value   Quoted market price   N/A   N/A
    D.7.    Available-for-sale financial assets (contingent consideration receivable):   Fair value   Under IAS 39, contingent consideration receivable on a divestment is a financial asset. The fair value of such assets is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.
    D.7.    Long-term loans and advances and other non-current receivables   Amortized cost   The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.
    D.7.    Financial assets recognized under the fair value option(a)   Fair value   Market value
    (net asset value)    		   N/A   N/A
    D.20.    Forward currency contracts   Fair value   Present value of
    future cash flows    		   Mid Market Spot   < 1 year: Mid Money Market
    > 1 year: Mid Zero
    Coupon
    D.20.    Interest rate swaps   Fair value   Present value of
    future cash flows    		   Mid Market Spot  

    < 1 year: Mid Money Market

    > 1 year: Mid Zero Coupon
    D.20.    Cross-currency swaps   Fair value   Present value of
    future cash flows    		   Mid Market Spot  

    < 1 year: Mid Money Market

    > 1 year: Mid Zero Coupon
    D.13.    Investments in mutual funds   Fair value   Market value
    (net asset value)    		   N/A   N/A
    D.13.    Negotiable debt instruments, commercial paper, instant access deposits and term deposits   Amortized cost   Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.
           In the case of debt with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements.
    D.17.    Debt   Amortized cost(b)   For debt with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).
    D.18.    Liabilities related to business combinations and to non-controlling interests (CVRs)   Fair value   Quoted market price   N/A   N/A
    D.18.    Liabilities related to business combinations and to non-controlling interests (other than CVRs)   Fair value(c)   Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.18.

     

      (a)

    These assets are held to fund a deferred compensation plan offered to certain employees.

     

      (b)

    In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).

     

      (c)

    For business combinations completed prior to application of the revised IFRS 3, contingent consideration is recognized when payment becomes probable (see Note B.3.1.).